The launch date of Teriflunomide in China

In July 2018, Teriflunomide (Teriflunomide) was approved by the National Medical Products Administration for marketing in China. It is the first oral disease-modifying therapy (DMT) drug approved in China for the treatment of multiple sclerosis (MS) and is sold under the trade name Aubagio. Teriflunomide, the active metabolite of leflunomide, is a once-daily oral disease-modifying therapy that has been shown to be effective in patients with relapsing forms of multiple sclerosis and those with a first clinical episode suggestive of multiple sclerosis. As the only disease-modifying therapy to show positive disability results in two Phase III trials, teriflunomide significantly slowed disability in patients with relapsing forms of multiple sclerosis.